The Latest Analyst Ratings for Nurix Therapeutics
Portfolio Pulse from Benzinga Insights
Nurix Therapeutics (NASDAQ:NRIX) has received 4 bullish, 1 somewhat bullish, and 1 indifferent rating from analysts in the last quarter. The average price target is $28.5, representing a significant upside from the current price of $6.28. However, this target is a 10.24% decrease from the previous average price target of $31.75.
October 13, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given Nurix Therapeutics a mostly bullish rating, with a significant upside predicted from its current price.
The bullish ratings and significant upside predicted by analysts suggest a positive short-term impact on Nurix Therapeutics' stock. However, the decrease in the average price target could indicate some caution.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100